Adam Maeder
Stock Analyst at Piper Sandler
(4.00)
# 405
Out of 4,814 analysts
81
Total ratings
51.52%
Success rate
10.02%
Average return
Main Sectors:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Reiterates: Overweight | $133 → $145 | $129.70 | +11.80% | 3 | Apr 17, 2025 | |
| RXST RxSight | Initiates: Neutral | $18 | $14.44 | +24.65% | 1 | Apr 15, 2025 | |
| RBOT Vicarious Surgical | Maintains: Neutral | $11 → $8.5 | $5.39 | +57.70% | 7 | Mar 18, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $70 → $73 | $71.56 | +2.02% | 13 | Feb 12, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $260 → $233 | $150.00 | +55.33% | 14 | Feb 10, 2025 | |
| RMD ResMed | Maintains: Neutral | $252 → $260 | $211.49 | +22.94% | 2 | Jan 31, 2025 | |
| ISRG Intuitive Surgical | Reiterates: Overweight | $538 → $670 | $482.40 | +38.89% | 18 | Jan 24, 2025 | |
| NSPR InspireMD | Reiterates: Overweight | $4.5 | $2.56 | +75.78% | 3 | Sep 17, 2024 | |
| M Macy's | Maintains: Hold | $20 → $21 | $11.01 | +90.74% | 2 | May 22, 2024 | |
| STIM Neuronetics | Reiterates: Overweight | $7 → $8 | $3.77 | +112.20% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $6.00 | +233.61% | 8 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $30 | $13.33 | +125.14% | 2 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.83 | +173.22% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 → $18 | $2.19 | +723.80% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $35.52 | +178.72% | 3 | May 5, 2022 |
Abbott Laboratories
Apr 17, 2025
Reiterates: Overweight
Price Target: $133 → $145
Current: $129.70
Upside: +11.80%
RxSight
Apr 15, 2025
Initiates: Neutral
Price Target: $18
Current: $14.44
Upside: +24.65%
Vicarious Surgical
Mar 18, 2025
Maintains: Neutral
Price Target: $11 → $8.5
Current: $5.39
Upside: +57.70%
Edwards Lifesciences
Feb 12, 2025
Maintains: Neutral
Price Target: $70 → $73
Current: $71.56
Upside: +2.02%
Inspire Medical Systems
Feb 10, 2025
Maintains: Overweight
Price Target: $260 → $233
Current: $150.00
Upside: +55.33%
ResMed
Jan 31, 2025
Maintains: Neutral
Price Target: $252 → $260
Current: $211.49
Upside: +22.94%
Intuitive Surgical
Jan 24, 2025
Reiterates: Overweight
Price Target: $538 → $670
Current: $482.40
Upside: +38.89%
InspireMD
Sep 17, 2024
Reiterates: Overweight
Price Target: $4.5
Current: $2.56
Upside: +75.78%
Macy's
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $11.01
Upside: +90.74%
Neuronetics
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $3.77
Upside: +112.20%
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $6.00
Upside: +233.61%
May 9, 2023
Maintains: Overweight
Price Target: $25 → $30
Current: $13.33
Upside: +125.14%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $1.83
Upside: +173.22%
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $2.19
Upside: +723.80%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $35.52
Upside: +178.72%